Lupin Sets Record with Maximum Diabetes Patients Onboarded in Real-World Evidence Study

Mumbai (Maharashtra) [India], April 22: In a groundbreaking achievement, Lupin Limited has set a new benchmark in Real-World Evidence (RWE) research by successfully onboarding 67,802 diabetes patients across 1,336 clinics for one of India’s largest single RWE studies conducted for vildagliptin and its combinations.

The study, which was officially confirmed on March 15, 2025, aimed to capture vital real-world data including demographics, disease duration, laboratory investigations, and treatment outcomes. The insights gathered are expected to…